Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Buy” by Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $131.86.

A number of research analysts recently issued reports on LNTH shares. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. JMP Securities cut their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial reissued a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company.

Lantheus Stock Performance

Shares of LNTH stock opened at $91.30 on Friday. The stock’s 50-day moving average is $95.36 and its two-hundred day moving average is $98.60. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a market cap of $6.35 billion, a price-to-earnings ratio of 15.19 and a beta of 0.45.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus in the third quarter valued at about $25,000. Signaturefd LLC lifted its holdings in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the period. Nkcfo LLC purchased a new stake in shares of Lantheus in the second quarter valued at approximately $47,000. UMB Bank n.a. raised its position in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus in the third quarter valued at $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.